<?xml version="1.0" encoding="UTF-8"?>
<p id="Par37">The impact of RSV on immunocompromised patients with myeloma following stem cell or solid organ transplantation is well known, being associated in 40â€“60% of cases with a progression from the upper to the lower respiratory tract [
 <xref ref-type="bibr" rid="CR13">13</xref>, 
 <xref ref-type="bibr" rid="CR21">21</xref>]. Mortality can reach 30% after developing pneumonia [
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
